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eﬁts to patients with ESRD, at a lesser cost. It may be more cost-
effective to manage patients starting on RRT with preemptive
KT or HD, than CAPD.
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Fecal incontinence (FI) is one of the most psychologically and
socially debilitating condition in an otherwise healthy individ-
ual. Sacral Nerve Stimulation (SNS) is the option in cases where
conservative treatments have been ineffective and before under-
going surgery procedures like dynamic graciloplasty or artiﬁcial
anal sphincter in patients with intact anal sphincter (IAS) and
before Sphincteroplasty in patients with structural deﬁcient anal
sphincter (SDAS). Interstim® is a relatively new effective and
safety therapy that has shown to be more effective than surgery
in almost all patients. OBJECTIVE: To asses the efﬁciency of
introducing Interstim® in management of patients suffering FI in
the Spanish setting using a cost-effectiveness model. METHODS:
A decision analytic model was developed to estimate the costs
and outcomes of patients with FI managed with and without
Interstim®. Clinical and economic data were retrieved from pub-
lished studies and an expert panel. The analysis was run over a
5 years time horizon from a NHS perspective and the primary
outcome was quality-adjusted life years (QALYs). Cost data were
obtained from SOIKOSTM Spanish’s health care costs database.
Costs and beneﬁts were actualized to euros 2004 and discounted
at 3% annum. Sensitivity analyses were performed in order to
handle uncertainty. RESULTS: Preliminary results show that the
introduction of Interstim® in the management of FI increases
treatment costs in 1211 in IAS patients and 1024 in SDAS
patients (5246 to 6456 and 7648 to 8671 respectively), yielding
to improvement in quality adjusted life expectancy of 0.234 and
0.228 respectively. Discounted cost per QALY gained of the
introduction of Interstim® are 5182 and 4486. CONCLUSIONS:
The use of Interstim® as an alternative to current surgical pro-
cedures in certain circumstances (as second or third treatment
line in IAS and SDAS IF patients) is associated to an improve-
ment of IF patients at a reasonable extra cost.
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OBJECTIVES: To compare both drugs in terms of efﬁcacy and
costs. METHODS: The efﬁciency of incontinence treatment, as
perceived by third party payer, will be calculated. Due to com-
parable efﬁcacy, a cost-minimisation-analysis was conducted to
evaluate the costs of a treatment of urinary incontinence with
trospium chloride and with oxybutynin. Based on data obtained
from literature, a decision tree model was compiled to portray
the course of treatment. Adverse drug reactions (ADR) were also
be considered. Costs for treatment of incontinence, treatment of
ADR, and for second-line therapy taken if the treatment failed,
will be taken into consideration. After calculation of all the
emerged costs, total costs were determined by means of the
DATA-program. To analyse the inﬂuence of different parameters
on total costs, from the perspective of the statutory health insur-
ance, two sensitivity-analyses were conducted. RESULTS: Tro-
spium chloride caused third party payer expenses amounting to
€2,032, whereby the expenses for oxybutynin were €1968.
Because of the higher drug costs of trospium chloride, the treat-
ment costs were accordingly 3.3 % higher. The model was
proven robust. CONCLUSION: Treatment of urinary inconti-
nence with trospium chloride is as efﬁcacious as the well-estab-
lished oxybutynin and costs are comparable despite the higher
price of trospium chloride. The advantages however of trospium
chloride over oxbutynin are obvious by its adverse event
proﬁle—the risk of ADR is reduced. From the above mentioned
facts, it may be concluded that the treatment of urinary inconti-
nence with trospium chloride offers an adequate treatment alter-
native from the perspective of the statutory health insurance in
Germany.
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OBJECTIVES: Since 1992, legislative actions were taken to face
the increasing pharmaceutical expenditure in Italy. In this
context, evaluating the cost of illness on the NHS and the patient
becomes crucial, especially for high prevalence conditions, like
females LUTS. METHODS: This economic evaluation is part of
the FLOW project, a 2-year observational study aimed at eval-
uating the frequency and clinical progression of symptoms in
Italian women suffering from LUTS for >=3 months presenting
at 39 Urology Centres. Data on NHS expenditure such as spe-
cialist visits, hospitalization, therapy and laboratory tests were
collected retrospectively between May 2002 and May 2003.
Direct costs sustained by patients were collected using the
Dowell-Bryant Incontinence Cost Index (DBICI) which investi-
gates costs of disposable pads, re-usable incontinence products,
laundry expenditure, health professional expenditure,
surgery/diagnostic investigation and medication. RESULTS:
Costs sustained by NHS: After a one-year follow-up, 550 women
[mean (SD) age = 53.5 (13.8) years] were evaluated. The direct
yearly total cost for this cohort was €284.943,08. Of the total
expense, more than half (50.8%) was devoted to surgical
therapy, 30% to laboratory and instrumental tests and 12.5%
to rehabilitative therapies. The estimated annual average direct
cost per patient with LUTS was €518,08. For the urinary incon-
tinence (UI) group the annual expense was €635,00. Costs sus-
tained by patients: 200 women with UI compiled the DBICI.
Estimated annual average expenditure per patient was 276.04
euro. Of the total personal expenditure, the disposable inconti-
nence products accounted for 38% and medication for 22%.
CONCLUSION: In Italy, little is known about the economic
impact of LUTS. UI seems to be the most expensive LUTS
problem from the NHS point of view. Diapers and medication
represent the most expensive products for the patient.
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